Impact of counterbalance between macrophage migration inhibitory factor and its inhibitor Gremlin-1 in patients with coronary artery disease

Atherosclerosis

Volumn 237, Issue 2, 2014, Pages 426-432

  Müller, Iris I ^a   Müller, Karin A L ^a   Karathanos, Athanasios ^a   Schönleber, Heiko ^a   Rath, Dominik ^a   Vogel, Sebastian ^a   Chatterjee, Madhumita ^a   Schmid, Martina ^a   Haas, Maximilian ^a   Seizer, Peter ^a   Langer, Harald ^a   Schaeffeler, Elke ^b   Schwab, Matthias ^a,b   Gawaz, Meinrad ^a   Geisler, Tobias ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

Acute coronary syndrome; Coronary artery disease; Grem1; MIF

Indexed keywords

C REACTIVE PROTEIN; GREMLIN 1; HIGH MOBILITY GROUP B1 PROTEIN; MACROPHAGE MIGRATION INHIBITION FACTOR; PROTEIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS;

EID: 84908674396     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.09.010     Document Type: Article

References (29)

1. Bernhagen J., Krohn R., Lue H., Gregory J.L., Zernecke A., Koenen R.R., Dewor M., Georgiev I., Schober A., Leng L., Kooistra T., Fingerle-Rowson G., Ghezzi P., Kleemann R., McColl S.R., Bucala R., Hickey M.J., Weber C. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat. Med. 2007, 13:587-596.
2. Schober A., Bernhagen J., Thiele M., Zeiffer U., Knarren S., Roller M., Bucala R., Weber C. Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation 2004, 109(3):380-385.
3. Kong Y.Z., Huang X.R., Ouyang X., Tan J.J., Fingerle-Rowson G., Bacher M., Mu W., Scher L.A., Leng L., Bucala R., Lan H.Y. Evidence for vascular macrophage migration inhibitory factor in destabilization of human atherosclerotic plaques. Cardiovasc Res. 2005, 65(1):272-282.
4. Kong Y.Z., Yu X., Tang J.J., Ouyang X., Huang X.R., Fingerle-Rowson G., Bacher M., Scher L.A., Bucala R., Lan H.Y. Macrophage migration inhibitory factor induces MMP-9 expression: implications for destabilization of human atherosclerotic plaques. Atherosclerosis 2005, 178(1):207-215.
5. Müller I.I., Müller K.A., Schönleber H., Karathanos A., Schneider M., Jorbenadze R., Bigalke B., Gawaz M., Geisler T. Macrophage migration inhibitory factor is enhanced in acute coronary syndromes and is associated with the inflammatory response. PLoS One 2012, 7(6):e38376.
6. Herder C., Illig T., Baumert J., Müller M., Klopp N., Khuseyinova N., Meisinger C., Martin S., Thorand B., Koenig W. Macrophage migration inhibitory factor (MIF) and risk for coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Atherosclerosis 2008, 200(2):380-388.
7. Mitola S., Ravelli C., Moroni E., Salvi V., Leali D., Ballmer-Hofer K., Zammataro L., Presta M. Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2. Blood 2010, 116:3677-3680.
8. -/- mice. J.Biol. Chem. 2013, 288:31635-31645.
9. Chang K., Weiss D., Suo J., Vega J.D., Giddens D., Taylor W.R., Jo H. Bone morphogenic protein antagonists are coexpressed with bone morphogenic protein 4 in endothelial cells exposed to unstable flow invitro in mouse aortas and in human coronary arteries: role of bone morphogenic protein antagonists in inflammation and atherosclerosis. Circulation 2007, 116:1258-1266.
10. Third universal definition of myocardial infarction. Eur. Heart J. 2012, 33:2551-2567.
11. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Cardiovasc Res. 1997, 35:2-3.
12. ICH harmonised tripartite guideline. Guideline for good clinical practice. J.Postgrad. Med. 2001, 47:45-50. 121-130, 199-203.
13. Directive 2001/20/EC of the European Parliament and of the Council of 4th April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Med. Etika Bioet. 2002, 9:12-19.
14. Gibson C.M., de Lemos J.A., Murphy S.A., Marble S.J., McCabe C.H., Cannon C.P., Antman E.M., Braunwald E. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction - a TIMI 14 substudy. Circulation 2001, 103:2550-2554. TIMI Study Group.
15. Yamashita A., Nishihira K., Matsuura Y., Ito T., Kawahara K., Hatakeyama K., Hashiguchi T., Maruyama I., Yagi H., Matsumoto M., Fujimura Y., Kitamura K., Shibata Y., Asada Y. Paucity of CD34-positive cells and increased expression of high-mobility group box 1 in coronary thrombus with type 2 diabetes mellitus. Atherosclerosis 2012, 224:511-514.
16. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation 1995, 92(3):657-671.
17. Shah P.K. Mechanisms of plaque vulnerability and rupture. J.Am. Coll. Cardiol. 2003 Feb 19, 41(4 Suppl.S):15S-22S.
18. Naghavi M., Libby P., Falk E., Casscells S.W., Litovsky S., Rumberger J., Badimon J.J., Stefanadis C., Moreno P., Pasterkamp G., Fayad Z., Stone P.H., Waxman S., Raggi P., Madjid M., Zarrabi A., Burke A., Yuan C., Fitzgerald P.J., Siscovick D.S., de Korte C.L., Aikawa M., Juhani Airaksinen K.E., Assmann G., Becker C.R., Chesebro J.H., Farb A., Galis Z.S., Jackson C., Jang I.K., Koenig W., Lodder R.A., March K., Demirovic J., Navab M., Priori S.G., Rekhter M.D., Bahr R., Grundy S.M., Mehran R., Colombo A., Boerwinkle E., Ballantyne C., Insull W., Schwartz R.S., Vogel R., Serruys P.W., Hansson G.K., Faxon D.P., Kaul S., Drexler H., Greenland P., Muller J.E., Virmani R., Ridker P.M., Zipes D.P., Shah P.K., Willerson J.T. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 2003, 108(14):1664-1672.
19. Naghavi M., Libby P., Falk E., Casscells S.W., Litovsky S., Rumberger J., Badimon J.J., Stefanadis C., Moreno P., Pasterkamp G., Fayad Z., Stone P.H., Waxman S., Raggi P., Madjid M., Zarrabi A., Burke A., Yuan C., Fitzgerald P.J., Siscovick D.S., de Korte C.L., Aikawa M., Airaksinen K.E., Assmann G., Becker C.R., Chesebro J.H., Farb A., Galis Z.S., Jackson C., Jang I.K., Koenig W., Lodder R.A., March K., Demirovic J., Navab M., Priori S.G., Rekhter M.D., Bahr R., Grundy S.M., Mehran R., Colombo A., Boerwinkle E., Ballantyne C., Insull W., Schwartz R.S., Vogel R., Serruys P.W., Hansson G.K., Faxon D.P., Kaul S., Drexler H., Greenland P., Muller J.E., Virmani R., Ridker P.M., Zipes D.P., Shah P.K., Willerson J.T. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation 2003, 108(15):1772-1778.
20. Zernecke A., Bernhagen J., Weber C. Macrophage migration inhibitory factor in cardiovascular disease. Circulation 2008, 117(12):1594-1602.
21. White D.A., Fang L., Chan W., Morand E.F., Kiriazis H., Duffy S.J., Taylor A.J., Dart A.M., Du X.J., Gao X.M. Pro-inflammatory action of MIF in acute myocardial infarction via activation of peripheral blood mononuclear cells. PLoS One 2013, 8(10):e76206.
22. Chan W., Duffy S.J., White D.A., Gao X.M., Du X.J., Ellims A.H., Dart A.M., Taylor A.J. Acute left ventricular remodeling following myocardial infarction: coupling of regional healing with remote extracellular matrix expansion. JACC Cardiovasc. Imaging 2012, 5(9):884-893.
23. Tanaka A., Shimada K., Namba M., Sakamoto T., Nakamura Y., Nishida Y., Yoshikawa J., Akasaka T. Relationship between longitudinal morphology of ruptured plaques and TIMI flow grade in acute coronary syndrome: a three-dimensional intravascular ultrasound imaging study. Eur. Heart J. 2008, 29(1):38-44.
24. Toutouzas K., Tsiamis E., Karanasos A., Drakopoulou M., Synetos A., Tsioufis C., Tousoulis D., Davlouros P., Alexopoulos D., Bouki K., Apostolou T., Stefanadis C. Morphological characteristics of culprit atheromatic plaque are associated with coronary flow after thrombolytic therapy: new implications of optical coherence tomography from a multicenter study. JACC Cardiovasc. Interv. 2010, 3(5):507-514.
25. Herder C., Baumert J., Zierer A., Roden M., Meisinger C., Karakas M., Chambless L., Rathmann W., Peters A., Koenig W., Thorand B. Immunological and cardiometabolic risk factors in the prediction of type 2 diabetes and coronary events: MONICA/KORA Augsburg case-cohort study. PLoS One 2011, 6(6):e19852.
26. Yu C.M., Lau C.P., Lai K.W., Huang X.R., Chen W.H., Lan H.Y. Elevation of plasma level of macrophage migration inhibitory factor in patients with acute myocardial infarction. Am. J. Cardiol. 2001, 88(7):774-777.
27. Chan W., White D.A., Wang X.Y., Bai R.F., Liu Y., Yu H.Y., Zhang Y.Y., Fan F., Schneider H.G., Duffy S.J., Taylor A.J., Du X.J., Gao W., Gao X.M., Dart A.M. Macrophage migration inhibitory factor for the early prediction of infarct size. J.Am. Heart Assoc. 2013, 2(5):e000226.
28. Boekholdt S.M., Peters R.J., Day N.E., Luben R., Bingham S.A., Wareham N.J., Hack C.E., Reitsma P.H., Khaw K.T. Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: the EPIC-Norfolk prospective population study. Am. J. Med. 2004, 117(6):390-397.
29. Sobierajski J., Hendgen-Cotta U.B., Luedike P., Stock P., Rammos C., Meyer C., Kraemer S., Stoppe C., Bernhagen J., Kelm M., Rassaf T. Assessment of macrophage migration inhibitory factor in humans: protocol for accurate and reproducible levels. Free Radic. Biol. Med. 2013, 63:236-242.